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Abstract
Primary sclerosing cholangitis (PSC) remains a rare but 
significant disease, which affects mainly young males 
in association with inflammatory bowel disease. There 
have been few advances in the understanding of the 
pathogenesis of the condition and no therapeutics with 
proven mortality benefit aside from liver transplantation. 
There remain areas of controversy in the management 
of PSC which include the differentiation from other 
cholangiopathies, in particular immunoglobulin G4 
related sclerosing cholangitis, the management of 
dominant biliary strictures, and the role of ursodeo-
xycholic acid. In addition, the timing of liver trans-
plantation in PSC remains difficult to predict with 
standard liver severity scores. In this review, we address 
these controversies and highlight the latest evidence 
base in the management of PSC.
Key words: Immunoglobulin G4 related sclerosing 
cholangitis; Cholangiocarcinoma; Primary sclerosing 
cholangitis; Liver transplantation; Dominant strictures
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: There have been few advances in therapeutics 
for primary sclerosing cholangitis (PSC) and there remain 
areas of controversy in the management of PSC. In this 
review, we address these controversies, which include 
the differentiation of PSC from other cholangiopathies, 
in particular immunoglobulin G4 related sclerosing cho-
langitis, the management of dominant biliary strictures, 
the role of ursodeoxycholic acid, and the timing of liver 
transplantation.
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INTRODUCTION
Primary sclerosing cholangitis (PSC) is a chronic cho­
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Controversies in the management of primary sclerosing 
cholangitis
lestatic disorder characterised by inflammation and 
fibrosis of intrahepatic and extrahepatic bile ducts, 
resulting in multifocal biliary strictures[1]. The patho­
genesis of PSC remains unclear but hypotheses 
include genetic factors[2], lymphocyte recruitment and 
activation[3], portal bacteraemia[4] and bile salt toxicity[5]. 
PSC commonly affects males[6] with a median age at 
diagnosis of 35 years[6,7]. In addition, there is a significant 
association with inflammatory bowel disease (IBD)[8], 
hepatobiliary malignancies[9] and colorectal cancer[10]. A 
key aspect in the management of PSC is surveillance for 
the development of these conditions. Patients commonly 
present with cholestatic liver enzymes and a normal 
bilirubin[8]. The demonstration of a cholangiopathy is 
essential for the diagnosis of PSC[11]. Characteristic 
ERCP findings include diffuse multifocal strictures and 
irregularities, with normal or minimally dilated segments 
in between giving rise to the characteristic beaded 
pattern[12]. The use of MRCP has been increasing, 
partially driven by the complication rate of 11% following 
ERCP[13], and a comparable sensitivity and specificity to 
ERCP[14].
PSC is strongly associated with IBD, with prevalence 
of 63%­81%[8,15], most commonly ulcerative colitis 
(UC), in 86%­88%[15,16]. The temporal relationship of 
the 2 conditions can be variable, although IBD usually 
precedes the diagnosis of PSC. Patients with colitis 
typically have mild symptoms and are sometimes 
asymptomatic[17]. Endoscopic findings are very different 
between PSC and non­PSC groups, with more pancolitis, 
backwash ileitis, and rectal sparing in those with 
PSC[16]. Colonoscopy with biopsies is recommended as 
part of the diagnostic work­up in any new diagnosis of 
PSC[18]. In addition, patients with PSC and IBD have a 
significantly higher risk of colorectal cancer than those 
with IBD alone[10] (OR = 4.79, 95%CI: 3.58­6.41).
To date, certain aspects remain controversial in the 
management of PSC. They include the differentiation 
of PSC and from other causes of sclerosing cholangitis 
in particular immunoglobulin G4 related sclerosing 
cholangitis (IgG4­SC), the optimal management of 
dominant biliary strictures at endoscopy, the role of 
ursodeoxycholic acid (UDCA), its optimal dose and likely 
benefit, and the timing of liver transplantation. In this 
review article we will address these controversies.
SEARCH STRATEGY
We searched PubMed using the following terms: “primary 
sclerosing cholangitis”, “secondary sclerosing cholangitis”, 
“cholangiocarcinoma”, “IgG4 related disease” and “liver 
transplantation”. We included data from full­text articles, 
published in English. Further relevant articles were 
identified from the reference lists of review articles and 
guidelines from liver societies.
THE DIFFERENTIAL DIAGNOSIS OF PSC
Secondary sclerosing cholangitis (SSC), includes a 
heterogeneous group of conditions where different 
insults (i.e., infections, thrombosis, iatrogenic, trauma) 
can give rise similar clinical characteristics to PSC[19] 
(Table 1). A single­centre series of 31 patients with SSC, 
identified a shorter transplant free survival (median 72 
mo) when compared to controls with PSC, and with no 
complicating cases of cholangiocarcinoma (CCA)[20]. A 
more recently described entity is sclerosing cholangitis 
in critically ill patients. This may be related to hepatic 
hypoperfusion and biliary cast formation[21], and has 
a particularly aggressive clinical manifestation with a 
reported transplant free survival of approximately 1 
year[22].
IgG4 disease was first described in 1995 in patients 
with pancreatitis, raised serum IgG levels and a 
response to corticosteroids[23], which was termed auto­
immune pancreatitis (AIP). Extra­pancreatic biliary 
changes that were found on ERCP, in addition to lympho­
plasmocytic infiltration and fibrosis on liver biopsy, 
suggested an extra­pancreatic biliary component to the 
disease[24]. This has now been termed IgG4­SC, and is 
the commonest extra­pancreatic manifestation of AIP[25].
IgG4­SC is an important differential diagnosis for 
PSC, with a different natural history and treatment 
profile. There are some subtle differences and similarities 
between PSC and IgG4­SC (Table 2). Similar to PSC, 
IgG4­SC has a male preponderance, however it usually 
presents in older patients[26]. The clinical presentation in 
patients with IgG4­SC is more commonly acute onset 
of obstructive jaundice, than is seen in classical PSC[25], 
and was evident in 75% in one series[27]. IgG4­SC can 
also be diagnosed in asymptomatic patients with AIP, 
either at initial diagnosis or during follow up. The data on 
rates of co­existent IBD are limited to small case series 
from Japan[27] and United Kingdom[28], which show much 
lower detection of IBD when compared to patients with 
PSC. Serum IgG4 is elevated in 76% of patients with 
AIP, and total IgG is elevated in 42%[29]. An elevated 
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Table 1  Differential diagnosis for primary sclerosing cholangitis
Vascular Hepatic artery thrombosis
Portal hypertension bilopathy 
Portal cavernoma associated cholangiopathy
Intra-arterial chemotherapy
Sickle cell disease related cholangiopathy
Trauma Trauma post cholecystectomy
Abdominal trauma
Infections AIDS related cholangiopathy
Recurrent pyogenic cholangitis
Benign Intraductal stone disease
Malignancy Cholangiocarcinoma
Autoimmune Autoimmune sclerosing cholangitis
IgG4 related sclerosing cholangitis
Systemic vasculitis
Other Recurrent pancreatitis
Sclerosing cholangitis in critically ill patient
TPN related cholangiopathy
Histocytosis X
IgG4: Immunoglobulin G4; TPN: Total parenteral nutrition; AIDS: Acquired 
immune deficiency syndrome.
serum IgG4 level however is not sufficient to diagnose 
IgG4­SC, especially as the optimal cut­off value has 
not been defined and may differ for subgroups of IgG4-
SC[30].
There are 4 cholangiographic patterns of disease 
which vary in the level of stricture location[31]. These 
are usually long smooth strictures as opposed to 
beading and band­like strictures in PSC. Depending 
on the pattern of disease, hepatobiliary malignancy 
may form part of the differential diagnosis, hence the 
role for ERCP to obtain samples from dominant stric­
tures[26]. Brush cytology during ERCP is beneficial in 
detecting malignancy, however intra­ductal or ampullary 
biopsies are required to confirm the diagnosis of IgG4-
SC. Histological features of IgG4 related disease are 
infiltration of plasma cells and IgG4 positive plasma 
cells, storiform fibrosis, and obliterative phlebitis[32,33]. 
Cholangioscopy in IgG4­SC patients has demonstrated 
dilated and tortuous vessels in 69%, a feature that was 
not observed in patients with PSC[34]. In addition, less 
scarring and pseudo diverticula were noted in IgG4­SC 
patients compared to the PSC patients. When a second 
procedure was carried out after steroids (32 to 93 d), a 
significant improvement in stenosis, dilated and tortuous 
vessels, and mass lesions were identified[34].
The cholangiopathy of IgG4­SC is very responsive 
to corticosteroids and an improvement in bilirubin can 
be detected within 8 wk of therapy[28]. We recommend 
30­40 mg prednisolone o.d. for 4 wk followed by a slow 
wean, blood test monitoring and imaging at 6 wk[26]. 
Regular clinical assessment in this period is required due 
to the potential risk of cholangitis and sepsis. A follow up 
study of IgG4 related disease patients, which included 
84 with IgG4­SC, demonstrated a response to steroids 
in 97% but also a high relapse rate of 50%, which was 
not predicted by initial or on treatment serum IgG4 
levels[35]. Five percent were diagnosed with cirrhosis 
(histological and clinical) and one patient required liver 
transplantation. It has been hypothesised that unlike 
PSC, which presents as a more indolent disease with 
established fibrosclerotic changes, the biliary strictures 
found in IgG4-SC are at an earlier more inflammatory 
stage of the disease process which is more responsive 
to steroids[36]. IgG4-SC patients have not been identified 
to develop CCA[37], which is in contrast to PSC which 
confers a significant risk of CCA[38].
MANAGEMENT OF DOMINANT BILIARY 
STRICTURE
A dominant stricture is defined as a narrow biliary 
stricture which impedes normal bile flow, with a dia­
meter < 15 mm in the CBD/CHD or < 10 mm in the 
hepatic duct[39]. In a follow up study of 9.8 years, a new 
dominant stricture was found in 63% of patients[40]. 
Where liver biopsies were available, those with more 
advanced liver disease histologically were more likely 
to have dominant strictures[39,40]. The mean survival 
of patients with dominant strictures was significantly 
poorer than those without[40] (14 years vs 23 years, P = 
0.01). Data from long­term follow up studies (7.1 and 9.8 
years), demonstrates that patients who developed CCA, 
almost all had pre­existing dominant strictures[40,41].
The most concerning differential diagnosis of a 
dominant stricture is CCA. When a new dominant 
stricture is identified, a malignant aetiology needs to 
be excluded using the combination of axial imaging, 
biliary cytology and/or histology. Therapy for dominant 
strictures should be offered to all symptomatic patients, 
and current guidelines recommend endoscopic dilatation 
with or without stenting[40]. A prospective study of 52 
patients with dominant strictures who underwent biliary 
intervention (stent or dilatation) identified a significantly 
better survival free of transplantation at 3, 5 and 7 
years, when compared to that predicted by the Mayo 
Risk Score[39].
Despite an improvement in prognosis with biliary 
intervention, the evidence for the ideal therapeutic 
strategy is not clear and guidelines suggest endoscopic 
dilatation, but do not give definitive guidance regarding 
stenting[40]. This decision is a balance between the 
likelihood of biochemical improvement and the risk of 
intervention. A large retrospective review of all biliary 
interventions performed for dominant strictures revealed 
a similar clinical and biochemical course independent 
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Table 2  Primary sclerosing cholangitis compared to immunoglobulin G4 related sclerosing cholangitis (adapted 
from Joshi 2014)
PSC IAC
Gender (M:F)  1.5:1 7:1
Age of onset Young (< 40 yr) Older (> 50 yr)
Presentation Cholestatic liver enzymes Obstructive jaundice
Cholangiogram Beading, band-like strictures, peripheral pruning Long smooth strictures, low CBD strictures
Cholangioscopy Dilated and tortuous vessels Scarring, pseudo diverticula
Raised serum IgG4 levels   < 20% > 70%
Pancreatic involvement < 5% > 80%
Cholangiocarcinoma    9% Rare
Association with IBD  80% < 10%
Response to steroids Rare (IgG4 + ve PSC)     97%
M: Male; F: Female; PSC: Primary sclerosing cholangitis; IgG4: Immunoglobulin G4; IBD: Inflammatory bowel disease.
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there was serial FISH polysomy detected with no overt 
evidence of malignancy, 69% were diagnosed with 
CCA upto 2.5 years post initial test[49]. FISH may play 
a role in patients with high pre­test probability of CCA, 
or where CCA is suspected with no clear radiological or 
histological evidence. However it needs to be used with 
caution due to the low sensitivity, and importantly the 
risks of repeated invasive tests and the implications of 
delaying or excluding patients from liver transplantation.
THE ROLE OF UDCA
UDCA is a hydrophilic bile acid which was studied in 
patients with PSC following the discovery of its efficacy 
in chronic cholestatic conditions, in particular primary 
biliary cirrhosis[50].
Small prospective studies using UDCA at different 
doses in patients with PSC showed improvement in 
symptoms and liver biochemistry (8­16 mg/kg[51], 
10 mg/kg[52]), as well as histology (13­15 mg/kg[53]). 
Further studies at standard (13­15 mg/kg)[54] and 
higher doses (17­23 mg/kg)[55] did not demonstrate any 
survival advantage or prevention of CCA, although none 
were powered sufficiently to answer this hypothesis. 
A more recent randomised placebo controlled study at 
high dose (28­30 mg/kg) was terminated early due to 
an interim analysis demonstrating significantly higher 
rate of serious adverse events in the high dose UDCA 
group[56]. A subsequent meta­analysis on the use of 
UDCA in PSC concluded that there is no significant 
difference in mortality, histology or risk of CCA, at both 
standard and higher dose[57], and guidelines advise 
against its use in PSC[18] (Table 3).
Patients with PSC and IBD have an increased risk 
of developing colorectal dysplasia compared to patients 
with IBD alone[10]. Although the true mechanisms for this 
increased risk remains unclear, one proposed hypothesis 
is the increased exposure of the colon to toxic bile 
acids[58]. Attention has therefore turned to UDCA with 
some data suggesting a possible chemo­preventative 
role for UDCA in reducing the incidence of colorectal 
cancer in PSC and UC patients[59]. A meta­analysis also 
suggested a benefit of using low­dose UDCA (8­13 
mL/kg per day) but there was significant heterogeneity 
of the studies[60]. A double­blind, placebo controlled 
multicentre trial of 56 patients with PSC and UC given 
high dose UDCA (28-30 mg/kg) identified a significantly 
increased risk of colorectal cancer and dysplasia on both 
univariate, HR = 4.44 (1.30­20.1), and multivariate 
analysis, HR = 5.97 (1.39­41.44), in those receiving 
UDCA[61]. At present based on published guidelines, 
the use of UDCA for chemo­prevention for colorectal 
dysplasia is not recommended[18].
THE ROLE AND TIMING OF LIVER 
TRANSPLANTATION
Liver transplantation is an effective treatment for PSC, 
of modality of intervention, although a lower procedure 
related complication rate was evident in the balloon 
dilatation group compared to those who underwent stent­
ing[42]. A trial of short term temporary biliary stents (mean 
11 d) demonstrated an improvement in symptoms, 
with only 20% requiring further intervention in 1 year 
and 40% in 3 years[43]. However, within the same study 
a procedure related complication rate of 15% was 
reported[43]. 
A prospective multicentre study of patients with 
compensated PSC without recent biliary intervention, 
comparing balloon dilatation to short­term plastic 
stenting (1­2 wk) is underway (www.clinicaltrials.gov, 
NCT01398917). The main endpoints of the study include 
re­intervention free survival time at 2 years, change in 
cholestatic symptoms and biochemistry at 3 mo, and 
adverse incidents. Data from this study may guide us 
towards the optimal management strategy for this group 
of patients.
Cholangioscopy allows for direct optical visualisation 
and guided biopsies of the biliary epithelium and biliary 
lesions. It is another diagnostic tool in the management 
of dominant strictures. In a multi­centre retrospective 
study of 52 patients with sclerosing cholangitis (48 
PSC, 4 IgG4­SC) who underwent 54 procedures for 
suspicious biliary strictures, the sensitivity and speci­
ficity (50% and 100%, respectively) for diagnosing 
malignancy was comparable to a control group of 
patients investigated for a single biliary stricture[44]. 
Failure of cannulation rate was higher in the sclerosing 
cholangitis group (15%), and was related to difficulty 
cannulating the narrowed bile duct. The adverse events 
rate was 17%, with 11% developing cholangitis post 
procedure despite prophylactic antibiotics.
A further single centre prospective study of patients 
with PSC referred for cholangioscopy, reported their 
findings in 41 consecutive patients[45]. Cholangioscopy 
identified ductal stones in 56% of patients (of which 30% 
were not previously identified on cholangiography), and 
achieved complete or partial clearance in approximately 
three quarters of patients. One patient was diagnosed 
with CCA. Two of the 8 patients who proceeded to 
transplant were diagnosed with CCA on their explants, 
both of whom had undergone cholangioscopy directed 
biopsies which were negative. It appears that the 
diagnostic accuracy may be related to difficulties in 
deciding which parts of a stricture to biopsy, especially 
as it may contain both inflammation and cancer[44]. The 
addition of narrow­band imaging increases the biopsy 
rate but does not improve the dysplasia detection rate[46].
The use of fluorescence in situ hybridisation (FISH) 
on ERCP brushing samples has been studied in patients 
with PSC and suspicion of CCA. A recent meta­analysis 
involving 828 patients from 8 studies, identified a 
pooled sensitivity and specificity of 68% and 70%, 
respectively, and 51% and 93% respectively for the 6 
studies characterising FISH polysomy[47]. In a patient 
with PSC, a dominant stricture and FISH polysomy, 
there was a 88% specificity for CCA[48], and where 
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with survival post­transplant 93.7% at 1 year, 86.4% 
at 5 years, 69.8% at 10 years[62]. The indications for 
liver transplantation are similar to other aetiologies 
of chronic liver disease, but also include intractable 
pruritus and recurrent cholangitis. Organ allocation 
varies according to national policy. Recurrence of PSC 
following liver transplantation occurs in up to 20% of 
patients at 5 years[63,64]. The diagnosis of PSC recurrence 
post­transplant can be challenging due to the variety 
of causes of biliary strictures and cholangiopathy in 
the post­transplant setting. After exclusion of these, in 
combination with a concordant liver biopsy, a diagnosis 
of PSC recurrence can be made[65]. In patients who 
develop PSC recurrence, re­transplant free survival is 
85% at 1 year and 45% at 5 years[66].
Identifying which patients will benefit from liver trans-
plantation, and the optimal timing for this is a challenge 
in the management of PSC, and many predictive models 
have been developed to optimise this. The Mayo Risk 
Score was initially devised following a single centre 
analysis of 174 patients with PSC[67]. Using multivariate 
analysis, age, log bilirubin, log haemoglobin, presence 
of IBD and liver biopsy stage, were identified as key 
parameters in predicting transplant­free survival. These 
parameters were incorporated into a statistical survival 
model which stratified patients into “low”, “intermediate”, 
and “high” risk[67]. The Mayo Risk Score for PSC has had 
numerous iterations over the last 20 years[68,69]. The 
latest version of the Mayo Risk Score incorporates age, 
log bilirubin, log aspartate aminotransferase, variceal 
bleeding and albumin[69] (Table 4). This model predicts 
survival over 4 years and classifies patients as “low”, 
“medium” and “high” risk.
Cholangiograms of 129 patients with PSC identified 
that high­grade and diffuse strictures of the intrahepatic 
ducts were markers of poor prognosis[70]. A retrospective 
review of 181 cholangiograms from 4 centres[71], utilised 
the Amsterdam Cholangiographic Classification System 
for PSC[72]. The intrahepatic and extrahepatic ducts are 
scored based on severity of cholangiographic changes, 
and combined to calculate a prognostic index, where a 
higher score is associated with a poorer prognosis. If a 
patient however has a normal cholangiogram, a score of 
0 is attributed and a score cannot be calculated, thereby 
making this model invalid for patients with small­duct 
PSC. Using this classification, a validation study was able 
to construct a model which could predict medium and 
long term prognosis in individual patients with PSC[73].
The enhanced liver fibrosis (ELF) test has recently 
been assessed to predict clinical outcomes in a cohort of 
patients with large­duct PSC[74]. Median transplant­free 
survival differed significantly in the tertiles based on 
ELF score and a cut­off value was calculated to stratify 
patients into “low­score” and “high­score” groups, with 
a sensitivity of 67% and specificity of 83%. Patients 
with higher ELF score had a shorter survival, which was 
confirmed in a validation group of 138 patients[74]. In a 
multivariate Cox regression analysis, the ELF score was 
associated with transplant­free survival independent of 
the Mayo Risk Score.
CCA remains a contraindication to liver trans­
plantation in the majority of liver transplant centres. A 
protocol was developed at the Mayo Clinic (inclusion 
criteria: < 3 cm lesion, no metastases, no prior abdo­
minal radiation therapy, no transperitoneal biopsy of 
the tumour, no prior attempt at resection with violation 
of the bile ducts), which included pre­transplant neo­
adjuvant chemo­irradiation, and a modified post­
transplant immunosuppression regimen[75]. Using this 
protocol reported outcomes were comparable to other 
Table 3  Important studies involving ursodeoxycholic acid
Ref. Dose and study design Number UDCA (number placebo) Follow up Parameter Outcome
Chazouillères et al[51] 8-16 mg/kg 15 6 mo Liver enzymes Improved
UDCA alone
O'Brien et al[52] 10 mg/kg 12 37 mo Liver enzymes Improved
UDCA alone
Beuers et al[53] 13-15 mg/kg        6 (8) 12 mo Liver enzymes Improved
UDCA vs placebo Histology Improved
Lindor et al[54] 13-15 mg/kg        51 (51) 2.2 yr Liver enzymes Improved
UDCA v placebo Time to treatment failure No change
Time to liver transplant No change
Olsson et al[55] 17-23 mg/kg        110 (109) 5 yr Liver enzymes No change
UDCA vs placebo Transplant free survival No change
Lindor et al[56] 28-30 mg/kg        76 (74) Terminated Liver enzymes Improved
UDCA vs placebo Primary end-point Increased
Serious adverse events Increased
UDCA: Ursodeoxycholic acid.
Parameter Weighting
Age + 0.03 × absolute value
Bilirubin + 0.54 × log
Aspartate aminotransferase + 0.54 × log
Variceal bleeding + 1.24 × yes/no
Albumin - 0.84 × absolute value
Table 4  Mayo risk score1
1The link is: http://www.mayoclinic.org/medical-professionals/model-
end-stage-liver-disease/revised-natural-history-model-for-primary-
sclerosing-cholangitis.
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indications for liver transplantation[76]. Of 215 patients 
who received neo­adjuvant chemotherapy, 136 patients 
proceeded to liver transplantation (87 with PSC), with 
92% 1 year and 74% 5 year survival. Twenty one 
percent of those who underwent operative staging 
were excluded from transplantation due to metastatic 
disease, and there was a 21% tumour recurrence post 
transplantation[77]. Unfortunately these promising results 
have not been reproduced at other centres[78]. There are 
currently several studies in progress in order to further 
understand the role for liver transplantation for CCA, and 
this data is eagerly awaited[79].
CONCLUSION
The management of patients with PSC continues to pose 
a challenge to clinicians worldwide. Although guidelines 
are available, there are few proven therapeutic options, 
and there remain clinical scenarios which lack a robust 
evidence base with which to guide management. Many 
of the commonly used diagnostic tests, particularly 
for the detection of hepatobiliary malignancy, lack an 
appropriate sensitivity and specificity. Until further 
advances in the field take place, the mainstay of mana-
gement should involve optimal biliary drainage, timely 
referral for liver transplantation and a low threshold for 
investigation for hepatobiliary or colorectal malignancy.
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